US 12,226,483 B2
Phosphor-containing drug activator, suspension thereof, system containing the suspension, and methods for use
Harold Walder, Oak Island, NC (US); Frederic A. Bourke, Jr., Aspen, CO (US); Zakaryae Fathi, Raleigh, NC (US); Wayne F. Beyer, Ivanhoe, VA (US); Mark Oldham, Durham, NC (US); Justus Adamson, Durham, NC (US); and Michael Nolan, Raleigh, NC (US)
Assigned to IMMUNOLIGHT, LLC, Detroit, MI (US); and DUKE UNIVERSITY, Durham, NC (US)
Filed by IMMUNOLIGHT, LLC, Detroit, MI (US); and DUKE UNIVERSITY, Durham, NC (US)
Filed on Nov. 30, 2021, as Appl. No. 17/538,770.
Application 17/538,770 is a continuation of application No. 16/074,707, granted, now 11,260,129, previously published as PCT/US2017/016138, filed on Feb. 2, 2017.
Claims priority of provisional application 62/304,525, filed on Mar. 7, 2016.
Claims priority of provisional application 62/290,203, filed on Feb. 2, 2016.
Prior Publication US 2022/0080045 A1, Mar. 17, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 31/37 (2006.01); A61K 41/00 (2020.01); A61N 5/06 (2006.01); A61N 5/10 (2006.01); A61K 45/06 (2006.01)
CPC A61K 41/0066 (2013.01) [A61K 31/37 (2013.01); A61N 5/062 (2013.01); A61N 5/10 (2013.01); A61K 45/06 (2013.01); A61N 2005/0661 (2013.01); A61N 2005/1098 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A method for treating a tumor in a subject in need thereof, comprising:
infusing 8-methoxypsoralen (8-MOP) and a phosphor-containing drug activator into the tumor in the subject; and
delivering a dose of x-rays to the subject for production of ultraviolet and visible light inside the subject to activate the 8-methoxypsoralen (8-MOP) and induce a persistent therapeutic response, said dose comprising a pulsed sequence of x-rays delivering from 0.5-2 Gy to the tumor,
wherein the phosphor-containing drug activator comprises an admixture of two or more phosphors capable of emitting the ultraviolet and visible light upon interaction with x-rays;
said two or more phosphors comprising Zn2SiO4:Mn2+ and (3Ca3(PO4)2Ca(F, Cl)2:Sb3+, Mn2+) at a ratio (Zn2SiO4:Mn2+):(3Ca3(PO4)2Ca(F, Cl)2:Sb3+, Mn2+)) of from 1:10 to 10:1; wherein each of said two or more phosphors have at least one coating selected from the group consisting of an ethyl cellulose coating and a diamond-like carbon coating.